NASDAQ:REPLReplimune Group Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Replimune Group Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $19.96 +0.20 (+1.01 %) (As of 06/2/2020 04:00 PM ET) Add Compare Share Today's Range$18.67Now: $19.96▼$20.2650-Day Range$10.71MA: $16.55▼$21.2252-Week Range$8.58Now: $19.96▼$22.13Volume190,446 shsAverage Volume104,675 shsMarket Capitalization$731.45 millionP/E RatioN/ADividend YieldN/ABeta3.33 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Preclinical trials to express an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Preclinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.Read More Beat the Market (BTM) Rank™ 2.5 Analyst's Opinion Consensus RatingReplimune Group has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $23.58, Replimune Group has a potential upside of 18.2% from its current price of $19.96.Amount of Analyst CoverageReplimune Group has only been the subject of 1 research reports in the past 90 days. Previous Next 2.3 Community Rank Outperform VotesReplimune Group has received 109 “outperform” votes. (Add your “outperform” vote.)Underperform VotesReplimune Group has received 131 “underperform” votes. (Add your “underperform” vote.)Community SentimentReplimune Group has received 54.58% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Replimune Group and other stocks. Vote “Outperform” if you believe REPL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe REPL will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldReplimune Group does not currently pay a dividend.Dividend GrowthReplimune Group does not have a long track record of dividend growth. Previous Next 2.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Replimune Group insiders have not sold or bought any company stock.Percentage Held by Insiders63.18% of the stock of Replimune Group is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions58.92% of the stock of Replimune Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Replimune Group are expected to decrease in the coming year, from ($1.54) to ($1.91) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Replimune Group is -15.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Replimune Group is -15.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioReplimune Group has a P/B Ratio of 4.58. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 2.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.36 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:REPL Previous Symbol CUSIPN/A CIKN/A Webwww.replimune.com Phone781-222-9600Debt Debt-to-Equity Ratio0.20 Current Ratio13.43 Quick Ratio13.43Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.36 per share Price / Book4.58Profitability EPS (Most Recent Fiscal Year)($1.33) Net Income$-30,830,000.00 Net MarginsN/A Return on Equity-29.68% Return on Assets-24.86%Miscellaneous Employees62 Outstanding Shares36,646,000Market Cap$731.45 million Next Earnings Date6/26/2020 (Estimated) OptionableNot Optionable NASDAQ:REPL Rates by TradingView Receive REPL News and Ratings via Email Sign-up to receive the latest news and ratings for REPL and its competitors with MarketBeat's FREE daily newsletter. Replimune Group (NASDAQ:REPL) Frequently Asked Questions How has Replimune Group's stock been impacted by COVID-19 (Coronavirus)? Replimune Group's stock was trading at $11.93 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, REPL stock has increased by 67.3% and is now trading at $19.96. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Replimune Group? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Replimune Group in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Replimune Group. When is Replimune Group's next earnings date? Replimune Group is scheduled to release its next quarterly earnings announcement on Friday, June 26th 2020. View our earnings forecast for Replimune Group. How were Replimune Group's earnings last quarter? Replimune Group Inc (NASDAQ:REPL) posted its earnings results on Thursday, February, 13th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.36) by $0.10. View Replimune Group's earnings history. What price target have analysts set for REPL? 6 brokers have issued 1-year target prices for Replimune Group's stock. Their forecasts range from $12.50 to $30.00. On average, they anticipate Replimune Group's stock price to reach $23.58 in the next twelve months. This suggests a possible upside of 18.2% from the stock's current price. View analysts' price targets for Replimune Group. Has Replimune Group been receiving favorable news coverage? News headlines about REPL stock have been trending positive on Wednesday, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Replimune Group earned a media sentiment score of 2.6 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news aboutReplimune Group. Who are some of Replimune Group's key competitors? Some companies that are related to Replimune Group include Novavax (NVAX), Alector (ALEC), Fate Therapeutics (FATE), Bill.com (RVMD), Sangamo Therapeutics (SGMO), SpringWorks Therapeutics (SWTX), Adverum Biotechnologies (ADVM), Twist Bioscience (TWST), Mesoblast (MESO), Editas Medicine (EDIT), Adaptimmune Therapeutics (ADAP), I-Mab (BDTX), Cortexyme (CRTX), Regenxbio (RGNX) and Coherus Biosciences (CHRS). View all competitors. What other stocks do shareholders of Replimune Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other Replimune Group investors own include Peabody Energy (BTU), Peabody Energy (BTUUQ), Myovant Sciences (MYOV), Pfizer (PFE), Fate Therapeutics (FATE), Immunomedics (IMMU), AbbVie (ABBV), Aerie Pharmaceuticals (AERI), Axsome Therapeutics (AXSM) and Cleveland-Cliffs (CLF). Who are Replimune Group's key executives? Replimune Group's management team includes the following people: Mr. Philip Astley-Sparke, Exec. Chairman, Sec. & Treasurer (Age 48)Dr. Robert Coffin, Pres, CEO & Director (Age 54)Dr. Colin Love, Chief Operating Officer (Age 61)Dr. Pamela Esposito, Chief Bus. Officer (Age 45)Stephen Gorgol, Chief Accounting Officer When did Replimune Group IPO? (REPL) raised $100 million in an initial public offering (IPO) on Friday, July 20th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO. What is Replimune Group's stock symbol? Replimune Group trades on the NASDAQ under the ticker symbol "REPL." Who are Replimune Group's major shareholders? Replimune Group's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Redmile Group LLC (8.13%), BlackRock Inc. (2.84%), Emerald Advisers LLC (2.17%), Emerald Mutual Fund Advisers Trust (2.13%), Victory Capital Management Inc. (1.22%) and Victory Capital Management Inc. (1.22%). Company insiders that own Replimune Group stock include Colin Love, Fund Iv Gp LP Omega, Fund Iv LP Omega, Jason P Rhodes, Joseph P Slattery, Philip Astley-Sparke and Robert Coffin. View institutional ownership trends for Replimune Group. Which major investors are selling Replimune Group stock? REPL stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Squarepoint Ops LLC, Morgan Stanley, Wells Fargo & Company MN, Emerald Mutual Fund Advisers Trust, Alps Advisors Inc., and Deutsche Bank AG. Company insiders that have sold Replimune Group company stock in the last year include Colin Love, Philip Astley-Sparke, and Robert Coffin. View insider buying and selling activity for Replimune Group. Which major investors are buying Replimune Group stock? REPL stock was bought by a variety of institutional investors in the last quarter, including Redmile Group LLC, Nuveen Asset Management LLC, Victory Capital Management Inc., Victory Capital Management Inc., BlackRock Inc., Ensign Peak Advisors Inc, AQR Capital Management LLC, and UBS Group AG. Company insiders that have bought Replimune Group stock in the last two years include Fund Iv Gp LP Omega, Fund Iv LP Omega, Jason P Rhodes, and Joseph P Slattery. View insider buying and selling activity for Replimune Group. How do I buy shares of Replimune Group? Shares of REPL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Replimune Group's stock price today? One share of REPL stock can currently be purchased for approximately $19.96. How big of a company is Replimune Group? Replimune Group has a market capitalization of $731.45 million. The company earns $-30,830,000.00 in net income (profit) each year or ($1.33) on an earnings per share basis. Replimune Group employs 62 workers across the globe. What is Replimune Group's official website? The official website for Replimune Group is www.replimune.com. How can I contact Replimune Group? Replimune Group's mailing address is 500 Unicorn Park, WOBURN MA, 01801. The company can be reached via phone at 781-222-9600 or via email at [email protected] This page was last updated on 6/3/2020 by MarketBeat.com Staff
